

Electronic Acknowledgement Receipt

EFS ID:	3974558
Application Number:	10657363
International Application Number:	
Confirmation Number:	3135
Title of Invention:	Ultra high affinity neutralizing antibodies
First Named Inventor/Applicant Name:	James F. Young
Customer Number:	20583
Filer:	Tamera Weisser/Eric Baclig
Filer Authorized By:	Tamera Weisser
Attorney Docket Number:	10271-159-999
Receipt Date:	22-SEP-2008
Filing Date:	08-SEP-2003
Time Stamp:	20:04:28
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	LAMPRECHT_J_Infect_Dis_211.pdf	508051 5a52ec528075fdded9721246eb1ef390fec855579	no	7

Warnings:

Information:

2	NPL Documents	LANDRY_Infec_Dis_166A_969.pdf	238876	no	2
			55b43923913a021192b31d15012af5bfe0906646		
Warnings:					
Information:					
3	NPL Documents	LOBUGLIO_PNAS_4220.pdf	511367	no	5
			ff95a18ec43f90df4aa9af11ac90cdf5922fee14		
Warnings:					
Information:					
4	NPL Documents	MACDONALD_N_Eng_J_Med_397.pdf	559029	no	4
			cea977d662006653fe9f3a11e04d44dab08cf0b0		
Warnings:					
Information:					
5	NPL Documents	MALLEY_J_Infect_Dis_1555.pdf	559932	no	7
			cc4157730feeb595a4b100c45edd0502c409de8b		
Warnings:					
Information:					
6	NPL Documents	MARKS_Biotechnology_779.pdf	607390	no	5
			cd37381325bb22df04439b8a0f29137819285e38		
Warnings:					
Information:					
7	NPL Documents	MCARTHUR-VAUGHAN_J_Med_Primatol_61.pdf	1180079	no	14
			aa0204be349974ff6d8626aceef595a23ab06523		
Warnings:					
Information:					
8	NPL Documents	MEDIMMUNE_BioSpace_Beat_Nov_6_2006.pdf	478035	no	4
			f77c313df0e2b55ad18cb35447d5739376103c6b		
Warnings:					
Information:					
9	NPL Documents	MEDIMMUNE_BioSpace_Beat_Sept_1_2005.pdf	458829	no	3
			dab348b6abd7ff05d679041fce0f6de5226f1b0		
Warnings:					
Information:					
10	NPL Documents	MEDIMMUNE_Synagis_Packag_e_Insert_1999.pdf	202018	no	1
			cb8a89227aed1e4f706a5f35fe0e123585e35db1		
Warnings:					
Information:					

11	NPL Documents	MEDIMMUNE- INC_Synagis_Package_Insert_2 002.pdf	265380	no	1
			e502d012bbc2da81b6d2225092f4932bb8b55fd9		
Warnings:					
Information:					
12	NPL Documents	MEISSNER_Antimicrob_Agents _Chemother_1183.pdf	621945	no	6
			0d94db14c45105742f0bb745e53d27c471e369b		
Warnings:					
Information:					
13	NPL Documents	Motavizumab_vs_Palivizumab_ Inpharma_5.pdf	132849	no	1
			2d48793a52122f2631186f1be0b324b18dc a840f		
Warnings:					
Information:					
14	NPL Documents	MURPHY_J_Virol_3907.pdf	396728	no	4
			4fa31a0e20c062d7cf757726e2ade4a5a36e 6a96		
Warnings:					
Information:					
15	NPL Documents	MURPHEY_Vaccine_185.pdf	374740	no	5
			2e991491c60af10b1e83e63037357860ed5 b98e2		
Warnings:					
Information:					
16	NPL Documents	NAVAS_J_Pediatr_348.pdf	547037	no	7
			2e9df8ddc77de87862350fd7e3c2abe9dcd a6ae		
Warnings:					
Information:					
17	NPL Documents	NGUYEN_Clin_Exp_Immunol_8 5.pdf	1203872	no	9
			7b1edf2d7dbfa0fa11395d64234dc5657f46 d5c0		
Warnings:					
Information:					
18	NPL Documents	PALOMO_J_Virol_4199.pdf	1130966	no	8
			517d92a2f29d4afb06e08c2009f8004786c7 78ff		
Warnings:					
Information:					
19	NPL Documents	Phys_Des_Ref_55th_Ed_1863. pdf	601114	no	3
			041d88cea1a9f8e3634e2b6f6dd70a73e92f 551e		
Warnings:					
Information:					

20	NPL Documents	PRINCE_Infect_Immun_81.pdf	471373	no	7
			36af2ec1666478022208e67553511e69f1812197		
Warnings:					
Information:					
Total Files Size (in bytes):			11049610		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					